OTLK
Outlook Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$1.38-0.72%
Price as of Jul 20, 2026
OTLK profitability
Outlook Therapeutics, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- -360.9%
- EBITDA margin
- —
- EBIT margin
- —
- Net margin
- —
- Free cash flow margin
- —
Returns
- Return on equity
- 210.2%
- Return on assets
- -278.4%
- Return on invested capital
- 3352.6%
- Asset turnover
- 0.02x
Cash efficiency
- Cash from operations
- -$47.0M
- Cash per share
- $0.06
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.